Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
RGA enters its November 5 earnings window with a stock that has drifted only modestly lower while short sellers are cutting back and options traders are quietly layering on more downside protection than usual.
The positioning picture is split in an interesting way. Short sellers are stepping back, not adding. Short interest has fallen 18% over the past week to roughly 1.2% of the free float, down from nearly 1.6% in mid-September. Borrow is essentially free at 0.51% cost to borrow, and availability is as loose as it gets, with shares available to borrow running at multiples of the current short position. There is no squeeze pressure here and no obvious bear thesis being pressed by the lending market. The ORTEX short score has also drifted lower, from around 31.9 in late September to 29.7 now, consistent with a market that is growing less interested in RGA as a short target.
Options tell a different story. The put/call ratio has moved to 0.29, well above its 20-day average of 0.12. That ratio was sitting below 0.05 through most of September, so the jump is material in context, roughly 1.5 standard deviations above the recent mean. Calls still dominate the open interest book by a wide margin, but the shift toward puts in recent sessions suggests some participants are hedging ahead of the November print rather than expressing fresh bullish conviction. The 52-week range on the PCR runs from 0.04 to 5.25, so the current level is far from extreme, but the directional move this week is worth noting.
The Street remains broadly constructive on RGA, with the consensus skewed toward Overweight ratings and a mean price target of around $277, roughly 10% above the current $251 close. Barclays trimmed its target from $290 to $286 this week, keeping an Overweight rating in place, a small markdown rather than a change of view. Earlier in August, JPMorgan, Wells Fargo and Morgan Stanley all raised their targets after the Q2 print, reflecting genuine confidence in the earnings trajectory even as Morgan Stanley remains at Equal-Weight. Factor positioning supports the bull view: the analyst recommendation differential ranks at the 95th percentile, and the dividend score ranks at the 98th percentile, both unusually strong reads. The PE of around 8.4 and a price-to-book just above 1.0 keep valuation undemanding for a company the Street models growing EPS at 8% to 10% per year. The bear case centres on Asia Pacific headwinds and the risk that benefit ratios deteriorate, an execution concern rather than a structural one.
Institutional ownership is stable and concentrated among long-only managers. BlackRock holds around 10.4% and has been adding modestly, while Harris Associates sits at 7.2% and Vanguard entities collectively account for another 10%. No activist 13D is on the register; all large holders have filed passive Schedule 13G disclosures. Recent insider activity is worth flagging for context: the EVP and Global Chief Risk Officer exercised options and sold shares worth approximately $2.1 million in August, a compensation-related cycle rather than a discretionary signal, but it does represent the only insider transaction in the recent window.
RGA's last two earnings releases each produced one-day moves of 2.5% and 4.2% to the upside, with the five-day window extending those gains further. Wikipedia attention for the stock is running modestly elevated relative to its own 90-day history, a z-score of 1.7 from Wikimedia Foundation data, suggesting retail interest has picked up but remains far from extreme. With the next print 29 days away, what to watch is whether the options hedge builds further into late October and whether any revision activity in analyst targets follows, Barclays trimmed first this week and others may follow if macro conditions for Asia Pacific business deteriorate further.
See the live data behind this article on ORTEX.
Open RGA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.